EGFR and silicosis: For example, nintedanib, a TKI inhibitor with FDA approval for IPF, has also shown positive results in silicosis in vivo.56 Consistently, our data found two novel TKI inhibitors for silicosis treatment, of which gefitinib was also previously used in IPF.33 Specifically, gefitinib strongly inactivated myofibrobalsts that acted as executors to elicit fibrosis via downregulating p-EGFR, while fostamatinib reduced lung inflammation by inhibiting p-SYK in macrophages.